{"generic":"Ethinyl Estradiol\/Norethindrone Acetate","drugs":["Ethinyl Estradiol\/Norethindrone Acetate","Femhrt 1\/5","Femhrt Lo","Junel 1.5\/30","Junel 1\/20","Loestrin 1.5\/30","Loestrin 1\/20","Microgestin 1.5\/30","Microgestin 1\/20"],"mono":[{"id":"8sqns0","title":"Generic Names","mono":"Ethinyl Estradiol\/Norethindrone Acetate"},{"id":"8sqns1","title":"Dosing and Indications","sub":{"0":{"id":"8sqns1b4","title":"Adult Dosing","mono":"<ul><li><b>Acne - Contraception:<\/b> 1 tablet ORALLY daily for 21 consecutive days followed by 1 week of no tablets<\/li><li><b>Contraception:<\/b> 1 tablet ORALLY daily for 21 consecutive days followed by 1 week of no tablets<\/li><li><b>Menopause - Moderate to severe abnormal vasomotor function:<\/b> femhrt(R), 1 tablet ORALLY daily; initiate therapy at the lowest effective dose and for the shortest duration consistent with treatment goals and risks<\/li><li><b>Postmenopausal osteoporosis, In women with an intact uterus; Prophylaxis:<\/b> femhrt(R), 1 tablet ORALLY daily; initiate therapy at the lowest effective dose and for the shortest duration consistent with treatment goals and risks<\/li><\/ul>"},"1":{"id":"8sqns1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy of femhrt(R) not established<\/li><li>use of Junel(R), Loestrin(R), Microgestin(R) or Tri-Legest(R) for contraception before menarche is not indicated<\/li><li>safety and efficacy of Tri-Legest(R) for acne in children less than 15 years of age not established<\/li><li><b>Acne - Contraception:<\/b> 15 years of age and older and after menarche has begun, 1 tablet ORALLY daily for 21 consecutive days followed by 1 week of no tablets<\/li><li><b>Contraception:<\/b> after menarche has begun, 1 tablet ORALLY daily for 21 consecutive days followed by 1 week of no tablets<\/li><\/ul>"},"3":{"id":"8sqns1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne - Contraception<\/li><li>Contraception<\/li><li>Menopause - Moderate to severe abnormal vasomotor function<\/li><li>Postmenopausal osteoporosis, In women with an intact uterus; Prophylaxis<\/li><\/ul>"}}},{"id":"8sqns2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/><ul><li>Junel(R), Loestrin(R), Microgestin(R), Tri-Legest(R): Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.<\/li><li>Femhrt(R): Estrogen alone or with a progestin should not be used for the prevention of cardiovascular disease or dementia. Increased risks of stroke, DVT, pulmonary embolism, myocardial infarction, and invasive breast cancer have been reported with estrogen plus progestin therapy. Increased risks of stroke and DVT have been reported with estrogen-alone therapy, along with increased risk for endometrial cancer in a woman with a uterus who uses unopposed estrogens. An increased risk of probable dementia in postmenopausal women aged 65 and older has been reported with estrogen alone and with estrogen plus progestin therapy. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration possible.<\/li><\/ul>"},{"id":"8sqns3","title":"Contraindications\/Warnings","sub":[{"id":"8sqns3b9","title":"Contraindications","mono":"<ul><li>anaphylactic reaction or angioedema to ethinyl estradiol\/norethindrone acetate tablet (femhrt(R)<\/li><li>arterial thromboembolic disease (eg, stroke or myocardial infarction), active or history of (femhrt(R)<\/li><li>breast cancer, known, suspected, or history of<\/li><li>carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia<\/li><li>cerebral vascular or coronary artery disease (Junel(R), Loestrin(R), Microgestin(R), Tri-Legest(R))<\/li><li>cholestatic jaundice of pregnancy or jaundice with prior pill use (Junel(R), Loestrin(R), Microgestin(R), Tri-Legest(R))<\/li><li>deep vein thrombophlebitis or thromboembolic disorders, history of (Junel(R), Loestrin(R), Microgestin(R), Tri-Legest(R))<\/li><li>deep vein thrombosis or pulmonary embolism, active or history of (femhrt(R))<\/li><li>genital bleeding, undiagnosed abnormal<\/li><li>hepatic adenomas or carcinomas (Junel(R), Loestrin(R), Microgestin(R), Tri-Legest(R))<\/li><li>hepatic impairment or disease (femhrt(R))<\/li><li>pregnancy, known or suspected<\/li><li>thrombophlebitis or thromboembolic disorders (Junel(R), Loestrin(R), Microgestin(R), Tri-Legest(R))<\/li><\/ul>"},{"id":"8sqns3b10","title":"Precautions","mono":"<ul><li>breast cancer; increased risk with the use of estrogens and progestins by postmenopausal women has been reported; monitoring recommended<\/li><li>arterial vascular disease risk factors (hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, obesity) should be managed appropriately cardiovascular disease risk factors (hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, obesity) should be managed appropriately<\/li><li>cardiovascular disorders; increased risk of cardiovascular events (myocardial infarction, stroke, venous thrombosis, and pulmonary embolism) has been reported; if these occur or are suspected, discontinue immediately<\/li><li>dementia; increased risk of developing probable dementia has been reported in postmenopausal women aged 65 years and older (femhrt(R))<\/li><li>venous thromboembolism risk factors (personal history, family history, obesity, systemic lupus erythematosus) should be managed appropriately<\/li><li>asthma; exacerbation may occur (femhrt(R))<\/li><li>bleeding irregularities (breakthrough bleeding and spotting) have been reported with the use of oral contraceptives, particularly during the first 3 months of use; consider nonhormonal causes and take adequate diagnostic measures to rule out malignancy or pregnancy<\/li><li>breast cancer with bone metastases; increased risk of severe hypercalcemia; discontinuation recommended if hypercalcemia occurs (femhrt(R))<\/li><li>conditions influenced by fluid retention (cardiac or renal dysfunction); estrogens may cause fluid retention; monitoring recommended<\/li><li>contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist<\/li><li>depression, history; monitoring recommended; discontinue if depression recurs to a serious degree<\/li><li>diabetes mellitus; exacerbation may occur (femhrt(R))<\/li><li>elevated blood pressure; substantial increases in blood pressure has been reported; monitoring recommended<\/li><li>endometriosis; exacerbation may occur (femhrt(R))<\/li><li>epilepsy; exacerbation may occur (femhrt(R))<\/li><li>gallbladder disease requiring surgery; 2- to 4-fold increased risk in postmenopausal women receiving estrogens has been reported<\/li><li>hepatic adenomas, benign, have been reported with oral contraceptive use; risk appears to increase after 4 or more years of use; rupture may cause death through intraabdominal hemorrhage<\/li><li>hepatic hemangiomas; exacerbation may occur (femhrt(R))<\/li><li>HIV infection (AIDS) or STDs; oral contraceptives do not protect against infection<\/li><li>hyperlipidemia; some progestogens may elevate LDL levels; monitoring recommended<\/li><li>hypertriglyceridemia, preexisting; estrogens may caused elevations of plasma triglycerides which may lead to complications including pancreatitis<\/li><li>hypoparathyroidism; risk of estrogen-induced hypocalcemia (femhrt(R))<\/li><li>hypothyroidism; estrogen administration leads to increased thyroid-binding globulin levels; monitoring recommended (femhrt(R))<\/li><li>impaired liver function, including past history of cholestatic jaundice; estrogens may be poorly metabolized; discontinue in cases of recurrence<\/li><li>migraine; exacerbation may occur (femhrt(R))<\/li><li>migraine (new onset or exacerbation) or development of headache with a new pattern which is recurrent, persistent, or severe; discontinue oral contraceptive and evaluate the cause<\/li><li>nonhysterectomized women; addition of a progestin during estrogen administration may decrease incidence of endometrial hyperplasia (femhrt(R))<\/li><li>ovarian cancer; an increased risk has been reported (femhrt(R))<\/li><li>prediabetic and diabetic women; glucose intolerance has been reported with oral contraceptive use; monitoring recommended<\/li><li>porphyria; exacerbation may occur (femhrt(R))<\/li><li>retinal vascular thrombosis has been reported; discontinue pending eye examination if a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine occurs; permanently discontinue if papilledema or retinal vascular lesions occur<\/li><li>surgery associated with increased risk of thromboembolism or prolonged immobilization; discontinue therapy at least 4 to 6 weeks prior to procedure due to increased risk of venous thromboembolism<\/li><li>systemic lupus erythematosus; exacerbation may occur (femhrt(R))<\/li><li>vascular disease; dose-related risk from oral contraceptives<\/li><li>vascular disease; persistence of risk for ever-users of oral contraceptives<\/li><\/ul>"},{"id":"8sqns3b11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"8sqns3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding if possible.  May inhibit lactation.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},{"id":"8sqns4","title":"Drug Interactions","sub":[{"id":"8sqns4b13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"8sqns4b14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"8sqns4b15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"8sqns5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal cramps, Abdominal pain (5.3% to 6.8%), Bloating symptom, Nausea<\/li><li><b>Neurologic:<\/b>Headache (5.7% to 6.2%)<\/li><li><b>Reproductive:<\/b>Break-through bleeding, Pain of breast (7.8% to 9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Myocardial infarction<\/li><li><b>Endocrine metabolic:<\/b>Breast cancer<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder<\/li><li><b>Hematologic:<\/b>Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Benign neoplasm of liver<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal vein<\/li><li><b>Reproductive:<\/b>Ovarian cancer<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><li><b>Other:<\/b>Breast cancer, Ovarian cancer<\/li><\/ul>"},{"id":"8sqns6","title":"Drug Name Info","sub":{"0":{"id":"8sqns6b17","title":"US Trade Names","mono":"<ul><li>Loestrin 1\/20<\/li><li>Loestrin 1.5\/30<\/li><li>Junel 1\/20<\/li><li>Junel 1.5\/30<\/li><li>Microgestin 1\/20<\/li><li>Microgestin 1.5\/30<\/li><li>Femhrt 1\/5<\/li><li>Femhrt Lo<\/li><\/ul>"},"2":{"id":"8sqns6b19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Estrogen<\/li><li>Estrogen\/Progestin Combination<\/li><li>Monophasic Contraceptive Combination<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"8sqns6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"8sqns6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"8sqns7","title":"Mechanism Of Action","mono":"Exogenous administration of ethinyl estradiol and norethindrone acetate is intended to mimic the actions of the endogenous hormones, which include the maintenance and development of the female reproductive system and secondary sexual characteristics. These hormones work by binding to nuclear receptors in estrogen-responsive tissue, thereby eliciting intracellular changes. Norethindrone acetate, a synthetic progestin, acts by countering estrogenic effects by decreasing the number of nuclear estradiol receptors and boosting local metabolism of estrogens to less active metabolites, or by inducing gene products that weaken responses to estrogen. Specific to contraception, ethinyl estradiol and norethindrone acetate act by inhibiting ovulation as well as altering the cervical mucus and endometrium.<br\/>"},{"id":"8sqns8","title":"Pharmacokinetics","sub":[{"id":"8sqns8b23","title":"Absorption","mono":"<ul><li>Ethinyl estradiol, Tmax: 1.8 hours<\/li><li>Ethinyl estradiol, Bioavailability: 43%  to 55%<\/li><li>Ethinyl estradiol, Effect of food: decreased rate but not extent of absorption (high-fat meal)<\/li><li>Norethindrone acetate, Tmax: 1.8 hours<\/li><li>Norethindrone acetate, Bioavailability: approximately 64%<\/li><li>Norethindrone acetate, Effect of food: 27% increase in bioavailability (high-fat meal)<\/li><\/ul>"},{"id":"8sqns8b24","title":"Distribution","mono":"<ul><li>Ethinyl estradiol, Protein binding: greater than 95% (albumin)<\/li><li>Norethindrone acetate, Protein binding: greater than 95% (albumin and sex hormone binding globulin)<\/li><li>Ethinyl estradiol and norethindrone acetate, Vd: 2 to 4 L\/kg<\/li><\/ul>"},{"id":"8sqns8b25","title":"Metabolism","mono":"<ul><li>Ethinyl estradiol, Hepatic: extensive via oxidation by CYP3A4 and conjugation<\/li><li>Ethinyl estradiol, gastrointestinal mucosa: portion of first-pass metabolism<\/li><li>Ethinyl estradiol: estriol, active; estrone, active<\/li><li>Ethinyl estradiol: sulfate and glucuronide conjugates, unknown; 2-hydroxy ethinyl estradiol, unknown<\/li><li>Norethindrone acetate, Hepatic: extensive via reduction then sulfate and glucuronide conjugation<\/li><li>Norethindrone acetate: ethinyl estradiol, active; sulfate and glucuronide conjugates, unknown<\/li><\/ul>"},{"id":"8sqns8b26","title":"Excretion","mono":"<ul><li>Ethinyl estradiol, Fecal: extensive, primarily as metabolites<\/li><li> Ethinyl estradiol, Renal: extensive, primarily as metabolites<\/li><li>Ethinyl estradiol, Total body clearance: 0.4 L\/hr\/kg<\/li><li>Norethindrone acetate, Fecal: extensive, primarily as metabolites<\/li><li>Norethindrone acetate, Renal: extensive, primarily as metabolites<\/li><li>Norethindrone acetate, Total body clearance: 0.4 L\/hr\/kg<\/li><\/ul>"},{"id":"8sqns8b27","title":"Elimination Half Life","mono":"<ul><li>Ethinyl estradiol: 24 hours<\/li><li>Norethindrone acetate: 13 hours<\/li><\/ul>"}]},{"id":"8sqns9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take exactly as directed and at intervals not exceeding 24 hours, preferably after the evening meal or at bedtime<\/li><li>therapy should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration<\/li><li>nonhormonal back-up contraception should be used if the patient initiates therapy later than the first day of menstruation or if she has intercourse in the 7 days after missing 2 or more active pills in a row<\/li><\/ul>"},{"id":"8sqns10","title":"Monitoring","mono":"<ul><li>appropriate bone mineral density is indicative of efficacy<\/li><li>improvement in severity of vasomotor symptoms is indicative of efficacy<\/li><li>acne, contraception: prediabetic and diabetic women should be carefully observed<\/li><li>acne, contraception: annual history and physical exam, including special reference to blood pressure, breasts, abdomen and pelvic organs (including cervical cytology and relevant laboratory tests)<\/li><li>acne, contraception: women receiving treatment for hyperlipidemia should be monitored closely<\/li><li>acne, contraception: blood pressure closely in women with a history of hypertension or hypertension-related diseases or renal disease<\/li><li>acne, contraception: women with a strong family history of breast cancer or who have breast nodules should be monitored closely<\/li><li>acne, contraception: observation of fluid retention for women with conditions which might be aggravated by fluid retention<\/li><li>acne, contraception: women with a history of depression should be carefully monitored<\/li><li>osteoporosis prophylaxis, vasomotor symptoms: thyroid function in patients who receive thyroid hormone replacement therapy<\/li><li>osteoporosis prophylaxis, vasomotor symptoms: yearly breast examinations; mammography examinations based on patient's age, risk factors, and prior mammogram results<\/li><li>osteoporosis prophylaxis, vasomotor symptoms: fluid status, especially in women with predispositions (eg, cardiac or renal impairment)<\/li><\/ul>"},{"id":"8sqns11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 2.5 MCG-0.5 MG, 5 MCG-1 MG, 20 MCG-1 MG, 30 MCG-1.5 MG<br\/><\/li><li><b>Femhrt 1\/5<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 5 MCG-1 MG<br\/><\/li><li><b>Femhrt Lo<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 2.5 MCG-0.5 MG<br\/><\/li><li><b>Gildess 1\/20<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 20 MCG-1 MG<br\/><\/li><li><b>Gildess 1.5\/30<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 30 MCG-1.5 MG<br\/><\/li><li><b>Jinteli<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 5 MCG-1 MG<br\/><\/li><li><b>Junel 1\/20<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 20 MCG-1 MG<br\/><\/li><li><b>Junel 1.5\/30<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 30 MCG-1.5 MG<br\/><\/li><li><b>Larin 1\/20<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 20 MCG-1 MG<br\/><\/li><li><b>Larin 1.5\/30<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 30 MCG-1.5 MG<br\/><\/li><li><b>Loestrin 21 1\/20<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 20 MCG-1 MG<br\/><\/li><li><b>Loestrin 21 1.5\/30<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 30 MCG-1.5 MG<br\/><\/li><li><b>Microgestin 1\/20<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norethindrone Acetate) 20 MCG-1 MG<br\/><\/li><\/ul>"},{"id":"8sqns12","title":"Toxicology","sub":[{"id":"8sqns12b31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"8sqns12b32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"8sqns12b33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},{"id":"8sqns13","title":"Clinical Teaching","mono":"<ul><li>Patients should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Inform postmenopausal women of the potential for serious adverse events related to hormone therapy, including cardiovascular disorders, malignant neoplasms, and probable dementia.<\/li><li>Instruct patient to immediately report signs\/symptoms of serious cardiovascular events such as myocardial infarction, stroke, venous thrombosis, or pulmonary embolism.<\/li><li>Advise patient to immediately report signs\/symptoms of retinal vein thrombosis (eg, sudden partial or complete loss of vision, or sudden onset of proptosis, diplopia, or migraine).<\/li><li>Drug may cause headache, abdominal pain, breast pain or tenderness and edema.<\/li><li>Tell patient to immediately report abnormal vaginal bleeding.<\/li><li>Tell patient to report any unexplained partial or complete loss of vision. In addition, patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>Tell patient to report any sudden onset or exacerbation of migraines or headaches that become more recurrent, persistent, or severe.<\/li><li>This drug should be taken every day, at the same time each day with not more than 24 hours between doses.<\/li><li>Advise patient to use a non-hormonal backup form of contraception for the first 7 days if a Sunday-start regimen is initiated.<\/li><li>Patient should avoid drinking grapefruit juice with this drug.<\/li><li>When used for contraception, instruct patient to take missed dose as soon as possible and take the next tablet at the regular time. Instruct patient to contact healthcare professional for instructions if more than 1 dose is missed. In many cases, this will necessitate the use of a back-up method of contraception.<\/li><\/ul>"}]}